← Home India · nd-india

Foresee Pharmaceuticals announces China NMPA grants marketing authorization for Camcevi 42 mg to treat advanced prostate cancer

Source: pharmabiz · 2026-10-13T00:00:00 UTC

Foresee Pharmaceuticals, a Taiwan and US─based biopharmaceutical company, announced that it was notified by its licensing partner, Changchun GeneScience Pharmaceutical Co., Ltd. (GenSci), that China's National

Full article text belongs to the original publisher. Moogle News shows the headline/summary and sends you to the source.

Read full story on publisher site →

Foresee Pharmaceuticals announces China NMPA grants marketing authorization for Camcevi 42 mg to treat advanced prostate cancer

Related in India

Vantiva's First 50G PON Device Now Commercially Available

McCain Foods to acquire Falcon Agrifriz Foods potato processing business

Best Electric Scooters And E-Bikes Under Rs. 85,000 For Daily Commuters, Starting Under Rs. 30,000

Koffee With Karan 9: Salman Khan to kick off new season of the controversial show – Watch promo

Citroen 2 CV Concept Revives An Icon With Retro Looks And Electric Power

Australian Open taps Adobe to drive year-round fan engagement through AI